Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Boehringer Ingelheim
McKesson
US Army
Cantor Fitzgerald
Deloitte
Accenture
Daiichi Sankyo
QuintilesIMS

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020329

« Back to Dashboard

NDA 020329 describes GLUCOTROL XL, which is a drug marketed by Pfizer and is included in one NDA. It is available from five suppliers. There is one patent protecting this drug. Additional details are available on the GLUCOTROL XL profile page.

The generic ingredient in GLUCOTROL XL is glipizide. There are eighteen drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the glipizide profile page.
Summary for 020329
Tradename:GLUCOTROL XL
Applicant:Pfizer
Ingredient:glipizide
Patents:1
Therapeutic Class:Blood Glucose Regulators
Formulation / Manufacturing:see details
Pharmacology for NDA: 020329
Ingredient-typeSulfonylurea Compounds
Medical Subject Heading (MeSH) Categories for 020329
Suppliers and Packaging for NDA: 020329
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329 NDA Roerig 0049-0170 N 0049-0170-01
GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329 NDA Roerig 0049-0174 N 0049-0174-03

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength5MG
Approval Date:Apr 26, 1994TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Mar 26, 2019Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength10MG
Approval Date:Apr 26, 1994TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Mar 26, 2019Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength2.5MG
Approval Date:Aug 10, 1999TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Mar 26, 2019Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE

Expired US Patents for NDA 020329

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-001 Apr 26, 1994 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-001 Apr 26, 1994 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-003 Aug 10, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-002 Apr 26, 1994 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Argus Health
Johnson and Johnson
Colorcon
Citi
Deloitte
Dow
Healthtrust
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.